DSIP

Delta sleep-inducing peptide is a short neuropeptide historically investigated in sleep, stress-response, neuroendocrine, pain, and withdrawal models.

Its molecular target has not been conclusively established. Reported effects may involve neuroendocrine and central nervous system signaling, but the biological role remains disputed.

Limited and inconsistent human evidence; older preclinical and small clinical literature exists.

Level III, Limited human evidence

The literature is heterogeneous, often old, and includes uncertain peptide identity, small cohorts, and limited replication.

A reliable modern human safety profile has not been established. CNS, endocrine, and immunogenicity risks remain insufficiently characterized.

No FDA-approved drug product; FDA has identified safety-information gaps for compounded emideltide/DSIP.

Supplied strictly for in-vitro and ex-vivo laboratory research. Not for human or veterinary administration, diagnostic, or therapeutic use. Import and regulatory compliance remain the responsibility of the receiving researcher.

• DSIP (Emideltide), 5 mgLyophilized

Every Cendrix lot ships with an HPLC purity chromatogram, mass-spectrometry identity confirmation, appearance and reconstitution observations, and endotoxin testing where applicable. Lot certificates are retrievable from the Quality page using the lot number printed on the vial.

External searches link to PubMed, ClinicalTrials.gov, Google Scholar, and FDA records. Cendrix does not endorse interpretations published in third-party sources.